SCHEMBL6488889

SCHEMBL6488889

CC(C)(C)OC(=O)N1C(Cc2ccc(Sc3ccccc3)cc2)COC1(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 1/20 0.39
NR1H2 P55055 2/20 0.38
NR1H3 Q13133 2/20 0.38
BRD4 O60885 1/20 0.36
MMP13 P45452 1/20 0.36
KLK7 P49862 1/20 0.35
HSD11B2 P80365 1/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP3A4 P08684 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
MAPT P10636 1/20 0.35
KEAP1 Q14145 1/20 0.35
NFE2L2 Q16236 1/20 0.35
ABCB1 P08183 2/20 0.34
EZH2 Q15910 1/20 0.34
GAA P10253 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488881 1.00 SPHK1 (0.39) SPHK1NR1H2NR1H3BRD4MMP13
SCHEMBL2288435 0.86 SPHK1 (0.39) SPHK1NR1H2NR1H3BRD4KLK7
SCHEMBL6487557 0.86 SPHK1 (0.39) SPHK1NR1H2NR1H3BRD4KLK7
SCHEMBL6487562 0.86 SPHK1 (0.39) SPHK1NR1H2NR1H3BRD4KLK7
SCHEMBL6541230 0.86 ALDH1A1 (0.39) ALDH1A1CYP3A4SMN1; SMN2HPGDPKM
SCHEMBL6541226 0.86 ALDH1A1 (0.39) ALDH1A1CYP3A4SMN1; SMN2HPGDPKM
SCHEMBL2290598 0.85 SPHK1 (0.43) SPHK1NR1H2NR1H3BRD4KLK7
SCHEMBL2290590 0.85 SPHK1 (0.43) SPHK1NR1H2NR1H3BRD4KLK7
SCHEMBL2295715 0.84 NR1H2 (0.39) SPHK1NR1H2NR1H3BRD4KLK7
SCHEMBL2295708 0.84 NR1H2 (0.39) SPHK1NR1H2NR1H3BRD4KLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-02-24 US disclosed
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-10-03 US disclosed
EP-1140849-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
WO-2000040560-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB1, ADRB2, ADRB3 SPHK1 874/4885NR1H2 21/4885NR1H3 23/4885
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB2, ADRB1, ADRB3 SPHK1 1034/4885NR1H2 27/4885NR1H3 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.